Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

[1]  A. Makris,et al.  Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer , 2019, JAMA oncology.

[2]  Marcus D. Goncalves,et al.  Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. , 2018, The New England journal of medicine.

[3]  J. Manola,et al.  Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Norikazu Masuda,et al.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[5]  A. Ravaud,et al.  Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  O. Delpuech,et al.  AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules , 2015, Molecular Cancer Therapeutics.

[7]  M. Ranson,et al.  First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 , 2015, Clinical Cancer Research.

[8]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[9]  D. Sabatini,et al.  mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin , 2013, Science.

[10]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.